Per Björkman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4166311/publications.pdf

Version: 2024-02-01

70 papers

983 citations

430442 18 h-index 28 g-index

70 all docs 70 docs citations

70 times ranked 1389 citing authors

#	Article	IF	CITATIONS
1	Cardiovascular effects of intrauterine exposure to maternal HIV and antiretroviral therapy in Ethiopian infants followed from fetal life. Aids, 2022, Publish Ahead of Print, .	1.0	2
2	Molecular Epidemiology and Transmission Dynamics of the HIV-1 Epidemic in Ethiopia: Epidemic Decline Coincided With Behavioral Interventions Before ART Scale-Up. Frontiers in Microbiology, 2022, 13, 821006.	1.5	1
3	HIV self-testing for men who have sex with men in Sweden. A cross-sectional study concerning interest to use HIV self-tests. Global Health Action, 2022, 15, 2021631.	0.7	3
4	Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia. Viruses, 2022, 14, 729.	1.5	8
5	Tuberculosis infection and stillbirth in Ethiopia—A prospective cohort study. PLoS ONE, 2022, 17, e0261972.	1.1	3
6	Cardiovascular Profile of South African Adults with Low-Level Viremia during Antiretroviral Therapy. Journal of Clinical Medicine, 2022, 11, 2812.	1.0	0
7	Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study. PLoS ONE, 2022, 17, e0268540.	1.1	5
8	Tuberculosis Infection in Women of Reproductive Age: A Cross-sectional Study at Antenatal Care Clinics in an Ethiopian City. Clinical Infectious Diseases, 2021, 73, 203-210.	2.9	16
9	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clinical Infectious Diseases, 2021, 72, 2079-2086.	2.9	46
10	A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral Syndrome. Clinical Infectious Diseases, 2021, 73, 832-841.	2.9	5
11	Drug Resistance in HIV-Positive Adults During the Initial Year of Antiretroviral Treatment at Ethiopian Health Centers. Open Forum Infectious Diseases, 2021, 8, ofab106.	0.4	1
12	Associations Between Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid Levels and Incidence of Invasive Cancer in People With HIV After Initiation of Combination Antiretroviral Therapy. Open Forum Infectious Diseases, 2021, 8, ofab131.	0.4	2
13	Absence of interferon-l̂» 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. Scandinavian Journal of Gastroenterology, 2021, 56, 855-861.	0.6	O
14	How does HIV testing modality impact the cascade of care among persons diagnosed with HIV in Ethiopia?. Global Health Action, 2021, 14, 1933788.	0.7	1
15	Expression of MicroRNAs Is Dysregulated by HIV While Mycobacterium tuberculosis Drives Alterations of Small Nucleolar RNAs in HIV Positive Adults With Active Tuberculosis. Frontiers in Microbiology, 2021, 12, 808250.	1.5	1
16	Interferon- \hat{l}^3 -Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV. Microbiology Spectrum, 2021, 9, e0181021.	1,2	2
17	Alternative biomarkers for classification of latent tuberculosis infection status in pregnant women with borderline Quantiferon plus results. Tuberculosis, 2020, 124, 101984.	0.8	7
18	Interest in Taking HIV Pre-exposure Prophylaxis Is Associated with Behavioral Risk Indicators and Self-Perceived HIV Risk Among Men Who Have Sex with Men Attending HIV Testing Venues in Sweden. Archives of Sexual Behavior, 2020, 49, 2165-2177.	1.2	8

#	Article	IF	CITATIONS
19	Brief Report: Interferon-γ–Inducible Protein 10—A Potential Marker for Targeted Viral Load Monitoring of Antiretroviral Treatment?. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 475-478.	0.9	3
20	Socio-economic condition and lack of virological suppression among adults and adolescents receiving antiretroviral therapy in Ethiopia. PLoS ONE, 2020, 15, e0244066.	1.1	7
21	Title is missing!. , 2020, 15, e0244066.		O
22	Title is missing!. , 2020, 15, e0244066.		0
23	Title is missing!. , 2020, 15, e0244066.		O
24	Title is missing!. , 2020, 15, e0244066.		0
25	Title is missing!. , 2020, 15, e0244066.		O
26	Title is missing!. , 2020, 15, e0244066.		0
27	Is lowâ€level <scp>HIV</scp> â€1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?. HIV Medicine, 2019, 20, 571-580.	1.0	19
28	Plasma Profiles of Inflammatory Markers Associated With Active Tuberculosis in Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Positive Individuals. Open Forum Infectious Diseases, 2019, 6, ofz015.	0.4	13
29	Validation of the Viral Load Testing Criteria – an algorithm for targeted viral load testing in HIVâ€positive adults receiving antiretroviral therapy. Tropical Medicine and International Health, 2019, 24, 356-362.	1.0	5
30	High rate of latent tuberculosis treatment completion in immigrants seeking asylum in Sweden. Infectious Diseases, 2018, 50, 678-686.	1.4	8
31	Both localized and systemic bacterial infections are predicted by injection drug use: A prospective follow-up study in Swedish criminal justice clients. PLoS ONE, 2018, 13, e0196944.	1.1	23
32	HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013. PLoS ONE, 2018, 13, e0205446.	1.1	22
33	Mortality and causes of death among people who inject amphetamine: A long-term follow-up cohort study from a needle exchange program in Sweden. Drug and Alcohol Dependence, 2018, 188, 274-280.	1.6	25
34	Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS ONE, 2018, 13, e0193589.	1.1	29
35	Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy. Drug and Alcohol Review, 2017, 36, 424-431.	1.1	8
36	Growth pattern in Ethiopian infants – the impact of exposure to maternal HIV infection in relation to socio-economic factors. Global Health Action, 2017, 10, 1296726.	0.7	11

#	Article	IF	CITATIONS
37	Vaccination against hepatitis B virus among people who inject drugs – A 20year experience from a Swedish needle exchange program. Vaccine, 2017, 35, 84-90.	1.7	16
38	Development of an algorithm for determination of the likelihood of virological failure in HIV-positive adults receiving antiretroviral therapy in decentralized care. Global Health Action, 2017, 10, 1371961.	0.7	3
39	Opioid and amphetamine dependence is associated with methicillin-resistantStaphylococcus aureus(MRSA): An epidemiological register study with 73,201 Swedish in- and outpatients 1997–2013. Infectious Diseases, 2017, 49, 120-127.	1.4	6
40	Long-term Outcome of Antiretroviral Treatment in Patients With and Without Concomitant Tuberculosis Receiving Health Center–Based Care—Results From a Prospective Cohort Study. Open Forum Infectious Diseases, 2017, 4, ofx219.	0.4	13
41	Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS ONE, 2017, 12, e0180761.	1.1	52
42	Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Global Health Action, 2016, 9, 29943.	0.7	18
43	Factors Associated with Early Mortality in HIV-Positive Men and Women Investigated for Tuberculosis at Ethiopian Health Centers. PLoS ONE, 2016, 11, e0156602.	1.1	10
44	Outcome of tuberculosis treatment in HIV-positive adults diagnosed through active versus passive case-finding. Global Health Action, 2015, 8, 27048.	0.7	20
45	Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-na $ ilde{A}^-$ ve HIV-positive adults at an Ethiopian hospital clinic. BMC Research Notes, 2015, 8, 702.	0.6	6
46	Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count. PLoS ONE, 2015, 10, e0144292.	1.1	24
47	Correlates of Skin and Soft Tissue Infections in Injection Drug Users in a Syringe-Exchange Program in Malmö, Sweden. Substance Use and Misuse, 2015, 50, 1529-1535.	0.7	27
48	Impaired CXCR1-dependent oxidative defence in active tuberculosis patients. Tuberculosis, 2015, 95, 744-750.	0.8	10
49	Hepatitis C Viremia Patterns in Incident Hepatitis C Infection and One Year Later in 150 Prospectively Tested Persons Who Inject Drugs. PLoS ONE, 2014, 9, e97022.	1.1	7
50	High rates of viral suppression in a cohort of HIV-positive adults receiving ART in Ethiopian health centers irrespective of concomitant tuberculosis. Journal of the International AIDS Society, 2014, 17, 19612.	1.2	3
51	Development of a clinical scoring system for assessment of immunosuppression in patients with tuberculosis and HIV infection without access to CD4 cell testing $\hat{a} \in \text{``results from a cross-sectional}$ study in Ethiopia. Global Health Action, 2014, 7, 23105.	0.7	7
52	Detection of lipoarabinomannan in urine for identification of active tuberculosis among <scp>HIV</scp> â€positive adults in <scp>E</scp> thiopian health centres. Tropical Medicine and International Health, 2014, 19, 734-742.	1.0	30
53	High Rates of Virological Suppression in a Cohort of Human Immunodeficiency Virus-Positive Adults Receiving Antiretroviral Therapy in Ethiopian Health Centers Irrespective of Concomitant Tuberculosis. Open Forum Infectious Diseases, 2014, 1, ofu039.	0.4	16
54	A Clinical Scoring Algorithm for Determination of the Risk of Tuberculosis in HIV-Infected Adults: A Cohort Study Performed at Ethiopian Health Centers. Open Forum Infectious Diseases, 2014, 1, ofu095.	0.4	29

#	Article	IF	CITATIONS
55	Intensified Tuberculosis Case-Finding in HIV-Positive Adults Managed at Ethiopian Health Centers: Diagnostic Yield of Xpert MTB/RIF Compared with Smear Microscopy and Liquid Culture. PLoS ONE, 2014, 9, e85478.	1.1	60
56	Decentralised paediatric HIV care in Ethiopia: a comparison between outcomes of patients managed in health centres and in a hospital clinic. Global Health Action, 2013, 6, 22274.	0.7	15
57	CD4 Cell Levels during Treatment for Tuberculosis (TB) in Ethiopian Adults and Clinical Markers Associated with CD4 Lymphocytopenia. PLoS ONE, 2013, 8, e83270.	1.1	29
58	The risk of cancer among persons with a history of injecting drug use in Sweden – a cohort study based on participants in a needle exchange program. Acta Oncológica, 2012, 51, 51-56.	0.8	7
59	Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. Journal of Viral Hepatitis, 2011, 18, 831-839.	1.0	30
60	Acceptance of HIV testing among women attending antenatal care in south-western Uganda: risk factors and reasons for test refusal. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 746-752.	0.6	56
61	Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. Aids, 2007, 21, 1641-1643.	1.0	26
62	GB virus C during the natural course of HIV-1 infection. Aids, 2004, 18, 877-886.	1.0	80
63	A Pilot with Pain in His Leg: Thigh Abscess Caused by Salmonella enterica Serotype Brandenburg. Journal of Clinical Microbiology, 2002, 40, 3530-3531.	1.8	11
64	"GB Virus C/Hepatitis G Virus Infection in Patients Investigated for Chronic Liver Disease and in the General Population in Southern Sweden". Scand J Infect Dis Vol. 33, no. 8, 2001. Scandinavian Journal of Infectious Diseases, 2001, 33, 798-798.	1.5	0
65	GB Virus C/Hepatitis G Virus Infection in Patients Investigated for Chronic Liver Disease and in the General Population in Southern Sweden. Scandinavian Journal of Infectious Diseases, 2001, 33, 611-617.	1.5	2
66	A case-control study of transmission routes for GB virus C/hepatitis G virus in Swedish blood donors lacking markers for hepatitis C virus infection. Vox Sanguinis, 2001, 81, 148-153.	0.7	27
67	Assessment of Liver Disease and Biochemical and Immunological Markers in Swedish Blood Donors with Isolated GB Virus C/Hepatitis G Virus Viremia. Vox Sanguinis, 2000, 78, 143-148.	0.7	18
68	Assessment of liver disease and biochemical and immunological markers in Swedish blood donors with isolated GB virus C/hepatitis G virus viremia. Vox Sanguinis, 2000, 78, 143-8.	0.7	9
69	GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors. , 1998, 54, 75-79.		13
70	Hepatitis C virus and GB virus C/hepatitis G virus viremia in Swedish blood donors with different alanine aminotransferase levels. Transfusion, 1998, 38, 378-384.	0.8	19